




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/85, 15/52, 9/00, 15/11, A61K 31/70, C12N 5/10</b>		(11) International Publication Number: <b>WO 95/15394</b>
<b>A1</b>		(43) International Publication Date: 8 June 1995 (08.06.95)
(21) International Application Number: PCT/US94/13670		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.          Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(22) International Filing Date: 30 November 1994 (30.11.94)		
(30) Priority Data: 08/160,058 1 December 1993 (01.12.93) US		
(71) Applicant: UNIVERSITY OF CONNECTICUT [US/US]; 213 Whetten Graduate Center, 438 Whitney Road Extension, Storrs, CT 06269-1133 (US).		
(72) Inventors: CARMICHAEL, Gordon, G.; 103 Richmond Lane, West Hartford, CT 06117 (US). BATT, David, B.; 2090 Stanley Street, No. 102, New Britain, CT 06053 (US). LIU, Zhong; 173 Edwards Street, New Haven, CT 06511 (US).		
(74) Agents: CARROLL, Alice, O. et al.; Hamilton, Brook, Smith & Reynolds, Two Militia Drive, Lexington, MA 02173 (US).		

(54) Title: TARGETED RNA DEGRADATION USING NUCLEAR ANTISENSE RNA



## (57) Abstract

The invention pertains to a novel method and construct for regulating gene expression through inhibition of gene expression by nuclear antisense RNA. The construct provides an efficient means for introducing, expressing and accumulating the antisense RNA in the nucleus. The antisense RNA hybridizes to the sense mRNA in the nucleus, thereby preventing both processing and cytoplasmic transport. The construct comprises a promoter, antisense sequences, and a *cis*- or *trans*- riboxyme which generates 3'-ends independently of the polyadenylation machinery and thereby inhibits the transport of the RNA molecule to the cytoplasm. The construct may also comprise a histone stem-loop structure that assists in stabilizing the transcripts against exonucleolytic degradation.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

TARGETED RNA DEGRADATION USING  
NUCLEAR ANTISENSE RNA

Background of the Invention

The polyoma virus genome is a small circular  
5 double-stranded DNA molecule whose early and late  
transcription units proceed in opposite directions from  
an intergenic regulatory region. In the early phase of  
a productive life cycle, the early genes (encoding the  
large, middle and small T antigens) are preferentially  
10 expressed. Before the initiation of viral DNA  
replication, few late-strand messages can be detected  
(Beard *et al.*, J. Virol. 17:20-26 (1976)). Once the  
infection enters the late phase (after the onset of DNA  
replication), late gene expression increases rapidly  
15 while the relative level of early gene expression is  
dramatically reduced.

The observation that polyoma virus mutants with  
temperature sensitive large T antigens overexpress their  
early genes at the nonpermissive temperature has led to  
20 the proposal that the viral early genes are negatively  
regulated by their own products (Farmerie and Folk,  
Proc. Natl. Acad. Sci. USA 81:6919-6923 (1984)). This  
autoregulation was thought to result from large T  
antigen binding to high affinity binding sites in the  
25 viral intergenic region and thereby inhibiting  
initiation from the early promoter (Fenton and Basilico,  
Virology 121:384-392 (1982)). However, it has been  
shown using nuclear run-on assays that the relative  
transcriptional activities from the early and late  
30 promoters change little throughout infection (Hyde-

-2-

DeRuyscher and Carmichael, Proc. Natl. Acad. Sci. USA 85:8993-8997 (1988)). Regulation of early gene expression after transcription initiation is also consistent with the data of Farmerie and Folk (Ibid.), who observed early gene repression by large T antigen even in constructs where this transcription was driven by a heterologous promoter. Taken together these results suggest that regulation of early gene expression is at a post-transcriptional level.

10 It has been shown that transcription termination of the late genes is inefficient during the late phase of infection (Hyde-DeRuyscher and Carmichael, Ibid.), allowing RNA polymerase II to continue around the circular viral genome multiple times. The resulting

15 giant primary transcripts are eventually processed by RNA splicing and polyadenylation, but unprocessed giant transcripts accumulate to high levels in the nucleus (Acheson, Mol. Cell. Biol. 4:722-729 (1984)). Due to the circularity of the polyoma genome, giant late-strand

20 transcripts contain sequences complementary to early-strand transcripts, serving as natural antisense RNA. These giant transcripts accumulate at the same time that early-strand RNAs become relatively less abundant.

There is a growing body of literature devoted to

25 antisense technology; however, this work has related only to cytoplasmic antisense RNA. (Murray, J.A.H. and Crockett, N., "Antisense Techniques: An Overview, " in Antisense RNA and DNA, (Wiley-Liss, Inc.) pp. 1-49 (1992)). There has been no work to date aimed at

30 producing antisense RNA accumulated in the nucleus.

#### Summary of the Invention

This invention pertains to the regulation of gene expression by nuclear antisense RNA. It is shown herein that the naturally occurring polyoma antisense early RNA

-3-

generated from the late transcription unit is almost exclusively present in the nucleus. Furthermore, it is shown herein that polyoma early-strand RNAs are reduced by expression and accumulation in the nucleus of antisense-early RNAs. It is demonstrated that antisense RNAs can be expressed and accumulated in the nucleus using a construct comprising a promoter, antisense sequences, and sequences encoding a *cis*-ribozyme and optionally a stem loop structure. The *cis*-ribozyme is incorporated into the antisense construct in order to generate 3'-ends independently of the polyadenylation machinery and thereby inhibit transport of the RNA molecule to the cytoplasm. The construct may optionally contain a histone stem loop structure to aid in stabilizing the transcripts against exonucleolytic degradation. This invention has application to several areas. It may be used as a therapeutic agent, targeting and inhibiting harmful native gene expression. It may also be used therapeutically to inhibit viral gene expression, thereby making cells resistant to and curing viral infection. This invention also has application as a research tool with the ability to inhibit expression of any targeted gene.

#### Brief Description of the Drawings

Figure 1 depicts the "late" transcription units of the polyoma mutants used in this study. Wild type (WT) encodes the late leader exon and two alternative splice sites, used for production of messages for the structural proteins VP3 and VP1. Mutant 5'ss $\Delta$  lacks 6 nucleotides (nt) (GTAAGT) at the 5' splice site bordering the late leader exon and expresses lower than wild type levels of antisense RNA to the viral early region (Barrett *et al.*, Nucleic Acids Res. 19:3011-3017 (1991)).

-4-

Figure 2 shows constructs expressing antisense early RNA in the nucleus. A. Antisense constructs used in this study. Construct  $\alpha$ E-RZ contains the antisense polyoma early region driven by the cytomegalovirus (CMV) promoter, with 3' end formation the result of cleavage by a *cis*-ribozyme. Construct E-RZ contains the same polyoma early region and the ribozyme sequence but no CMV promoter or polyoma replication origin. Construct Py-CMV contains only the CMV promoter and polyoma replication origin. The orientation of the polyoma early region is indicated by the arrowheads. The RNA probe Ribo-Ava is also shown. B. Sequence of the ribozyme and the histone stem-loop structure used in the construction of the plasmids shown in panel A. The vertical arrow indicates the cleavage site of the *cis*-ribozyme. The optional histone stem-loop structure used to stabilize the transcripts against possible exonucleolytic degradation is indicated.

Figure 3 illustrates subcellular distribution of antisense RNA transcripts produced by construct  $\alpha$ E-RZ. This subcellular distribution was determined in cells cotransfected with construct  $\alpha$ E-RZ (the antisense expression vector) and mutant 5'ssa (the target plasmid). Mutant 5'ssa was used because it overexpresses early RNA and allows  $\alpha$ E-RZ replication. Virtually all antisense RNA produced from construct  $\alpha$ E-RZ remains in the nucleus. It is also evident that ribozyme cleavage is incomplete, with only about 80% of the transcripts being cleaved. However, uncleaved transcripts also remain in the nucleus, as do the antisense-early transcripts from mutant 5'ssa.

Figure 4 shows dose-dependent inhibition of early-strand RNA accumulation by nuclear antisense RNA in trans. A. Inhibition of early-strand RNAs by antisense RNA in trans. Lane 1: wild type transfection; lanes 2-

-5-

5: the same amount of mutant 5'ssa was transfected by itself (lane 2), or co-transfected with a 9 fold molar excess of  $\alpha$ E-RZ (lane 3), E-RZ (lane 4) and Py-CMV (lane 5), respectively. B. Dose-dependent effect of antisense RNA on polyoma early transcripts. The same amount of 5'ssa was co-transfected with nuclear antisense RNA expression vector  $\alpha$ E-RZ at various molar ratios as indicated. The relative levels of early-strand RNAs are shown. Values have been corrected for probe length and U content. The numbers shown represent the average of two independent sets of experiments.

#### Detailed Description of the Invention

The present invention pertains to a novel method and construct for regulating gene expression through inhibition of gene expression by nuclear antisense RNA. The construct provides an efficient means for introducing, expressing and accumulating the antisense RNA in the nucleus. The antisense RNA hybridizes to the sense mRNA in the nucleus, thereby preventing both processing and cytoplasmic transport. The construct comprises a promoter, an origin of replication, antisense sequences, and a cis- or trans-ribozyme which generates 3'-ends independently of the polyadenylation machinery and thereby inhibits the transport of the RNA molecule to the cytoplasm. The construct may also comprise a histone stem-loop structure that assists in stabilizing the transcripts against exonucleolytic degradation.

The advantages of this invention over prior cytoplasmic antisense technology are three-fold. First, this invention closely mimics the system of naturally-occurring antisense regulation seen in a variety of organisms, indicating that it is a natural means for studying antisense regulation of gene expression. Also,

-6-

this invention solves at least one problem created by cytoplasmic antisense RNA, namely the activation of interferon by double stranded RNAs. There is no indication that nuclear antisense RNA causes interferon  
5 activation, and therefore there is less risk of adverse effects on the cell. (Lengyel, P., Journal of Interferon Research 7:511-519 (1987)). Furthermore, the efficiency of nuclear antisense RNA far exceeds that of cytoplasmic RNA. While in cytoplasmic RNA experiments  
10 the ratio of antisense to sense transcripts required for inhibition is typically on the level of 100 or 1000 to 1, data from nuclear antisense experiments indicates that the same level of regulation can be achieved with an antisense to sense ratio of as little as 5 to 1.  
15 This enhanced effectiveness is of great advantage both from an efficiency and cost-effectiveness standpoint.

Once introduced into the cell nucleus, the construct begins expressing the antisense sequences following the promoter. The construct contains none of  
20 the usual transcription termination sequences (typically associated with polyadenylation signals); instead a *cis*- or *trans*-ribozyme (SEQ ID NO. 1) is inserted to cleave the transcript without normal polyadenylation. This variation prohibits transportation of the antisense  
25 sequences from the nucleus to the cytoplasm. As the antisense sequences accumulate in the nucleus, they hybridize to their complementary sense mRNA transcripts. It is believed that the formation of these hybrids prevents processing and cytoplasmic transport of the  
30 mRNA, as these hybrids are shown to remain in the nucleus and are eventually degraded. By hybridizing to a targeted gene, the antisense transcripts can regulate and inhibit expression of that gene. This function has utility in both therapeutic and research applications.



-7-

The promoter segment can be chosen from a wide range of constitutive or inducible promoters. Of particular interest but not exclusive are the constitutive promoters of the human cytomegalovirus (CMV) and Rous sarcoma virus (RSV), as well as the Simian virus 40 and Herpes simplex promoters. Useful inducible promoters include antibiotic resistant promoters, heat-shock promoters, the hormone-inducible mammary tumor promoter and the metallothionein promoter.

The ribozyme component is included for the purpose of producing the 3' end independent of the cellular polyadenylation machinery. A *cis*-ribozyme with the ability to generate 3' ends in this manner is expected to achieve the desired result; however, of particular interest are the hammerhead *cis*-ribozyme (described in the Examples) and the human hepatitis delta virus ribozyme, which is believed to cleave transcripts faster and more efficiently than the hammerhead ribozyme. *Trans*-ribozymes can be used as an alternative.

This invention has application to the regulation of genes, and therefore the antisense sequences of interest are numerous. However, the sequence of the target gene should be known before its complementary antisense can be created. Thus, antisense sequences can be utilized based on the sequence of the gene desired for targeting.

The construct of this invention may optionally contain histone stem-loop structure for the purpose of stabilizing the cleaved antisense transcript against exonucleolytic degradation. However, depending on the desired duration of the result, this component may be omitted. In fact, published evidence (Eckner *et al.*) suggests that this structure stabilizes RNAs only in the cytoplasm.

-8-

In a preferred embodiment, regulation of target gene expression is achieved using a novel RNA construct shown in Figure 2A. This construct,  $\alpha$ E-RZ, contains sequences encoding a self-cleaving ribozyme (Figure 2B),  
5 flanked by a number of unique restriction enzyme cleavage sites, to facilitate cloning into other constructs. Immediately upstream of the ribozyme is a histone stem-loop structure to possibly retard degradation. The ribozyme cassette is inserted into  
10 standard cloning vector pBlueScript SKII. This ribozyme cassette is then excised and inserted into construct  $\alpha$ E-RZ (Figure 2A). This preferred embodiment incorporates a functional polyoma virus replication origin (nt 4636-96) to allow replication and amplification in mouse  
15 cells in the presence of large T antigen. Construct  $\alpha$ E-RZ also contains a promoter derived from the human cytomegalovirus (CMV) downstream from the origin of replication. A number of unique restriction enzyme cleavage sites for insertion of antisense sequences are  
20 downstream of the promoter sequence. Located between the promoter and ribozyme cassette are the polyoma antisense-early sequences. These sequences include polyoma nt 359-2908, spanning from about 230 base pairs (bp) downstream of the early TATA consensus sequence to  
25 a nucleotide 5 bp upstream of the early polyadenylation signal, AAUAAA.

Mouse NIH 3T3 cells were co-transfected with construct  $\alpha$ E-RZ and mutant 5'ssa. This polyoma virus mutant lacks 6 nt at the 5' splice site bordering the  
30 late leader, and overexpresses early-strand RNA by approximately 3 fold in comparison with wild type (Figure 1). Thus, this mutant was used in place of wild type polyoma virus to allow more accurate determinations of antisense regulation. Nuclear and cytoplasmic RNA  
35 samples were isolated, and these samples were probed

-9-

with an RNA probe that detects antisense early sequences from both constructs. The results (Figure 3) showed that essentially all antisense RNA produced from construct  $\alpha$ E-RZ remains in the nucleus, as does the RNA from the mutant 5'ssa. In further experiments a constant amount of construct 5'ssa was co-transfected into NIH 3T3 cells with increasing levels of  $\alpha$ E-RZ, and early RNA levels from construct 5'ssa were measured using an RNase protection assay as described in the Examples. These results (Figure 4) confirm that while mutant 5'ssa over expresses nuclear early RNAs relative to wild type, when this construct is co-transfected with a nine-fold excess of construct  $\alpha$ E-RZ early RNA expression was reduced to approximately the level of wild type expression. Control co-transfections using the same amounts of control constructs E-RZ, a promoterless version of  $\alpha$ E-RZ and Py-CMV, the same as  $\alpha$ E-RZ but lacking polyoma early antisense regions (Figure 2A) showed no decrease in early RNA levels from 5'ssa (Figure 4A, lanes 4 and 5). Figure 4B shows the dose-response analysis. Increasing amounts of  $\alpha$ E-RZ resulted in a striking diminution in 5'ssa early-strand RNA levels. DNA replication assays were performed to ensure that observations did not result from change in level of DNA replication.

To further illustrate the generality of the method, a vector using the Rous sarcoma virus promoter was used to drive expression of antisense RNA to the bacterial chloramphenicol acetyltransferase (CAT) gene in cotransfection experiments in mouse 3T3 cells. The assay shows that a six-fold excess of antisense-expressing plasmid leads to about a ten-fold reduction in CAT gene expression.

In another embodiment, specific sequences are incorporated into the nuclear antisense RNAs of the

-10-

construct to increase their levels. Specifically, it is believed that a sequence containing part of a recognized RNA splicing signal will improve the stability of the nuclear RNA molecules when placed near their 5' ends.

- 5 In an alternate embodiment, the *cis*-ribozyme of construct  $\alpha$ E-RZ is replaced with another ribozyme that is derived from the human hepatitis delta virus. It is reported that this ribozyme is far more efficient in vivo, compared to the ribozyme exemplified herein, and  
10 this may lead to higher levels of expressed nuclear antisense RNA.

- Another embodiment of this invention incorporates sequences derived from the human Epstein Barr virus which will allow DNA replication. These sequences  
15 include the "oriP" sequence and the EBNA-1 gene; thus the vector will be able to replicate every time the cell replicates, and thereby be maintained in the cell over long periods of time.

- In an alternate embodiment, the vector can be used  
20 to deliver not only antisense RNA but also antisense ribozymes that are capable of cleaving targeted RNA molecules *in trans*. There is growing literature on *trans*- ribozyme RNA cleavage, but again all systems use molecules that are targeted to the cytoplasm rather than  
25 the nucleus. (Steinecke, et al., EMBO J. 11:1525-1530 (1992)).

- In another embodiment, the early region of the monkey virus SV40 (which infects all primate cells) can be removed and replaced with the nuclear antisense  
30 expression cassette as described above. The SV40 late region can be left intact, and these molecules will be introduced into monkey cells that express the SV40 early proteins (COS cells), thereby allowing efficient replication of these molecules. The result of this  
35 transfection will be the production of non-viable

-11-

progeny virus particles, which are capable of expressing antisense RNA. Virus can be recovered from transfected cultures of COS cells and used to infect progeny cells. These viruses can enter cells and express the antisense genes, but are incapable of replication and cannot express SV40 late-region genes. This will allow delivery of nuclear antisense molecules efficiently and simultaneously to a large number of cells, including human cells.

- 10 This invention can be formulated in a preparation comprising the construct and a physiologically acceptable carrier. The preparation of this invention can be administered orally (e.g., capsular, tablet or liquid formulation), parenterally (e.g.,  
15 intramuscularly, intravenously, subcutaneously) or topically in dosage formulations containing physiologically acceptable vehicle and optional adjuvants and preservatives. Suitable physiologically acceptable vehicles include saline, sterile water,  
20 Ringer's solution and isotonic sodium chloride solutions. The specific dosage level of active ingredient will depend upon a number of factors, including biological activity of the particular preparation, age, body weight, sex, general health and  
25 clinical diagnosis.

- This invention also has utility as a research tool, in that it allows the regulation and inhibition of expression of various genes. This ability to selectively inhibit gene expression has potential for  
30 the study of virtually any gene expressed in eukaryotic cells.

The following Examples are offered for the purpose of illustrating the present invention and are not to be construed to limit the scope of this invention.

-12-

Exemplification

The teachings of all references are incorporated herein by reference.

Example 1: Materials

- 5 All restriction enzymes, T4 DNA ligase, large fragment of DNA polymerase (Klenow enzyme) and T4 polynucleotide kinase were from New England Biolabs and were used as suggested by the manufacturer. Calf intestine alkaline phosphatase was from Boehringer
- 10 Mannheim. An RNase T1/T2 mixture was made and used as described (Lichtler et al., Biotechniques 12:231-232 (1990)). T3 and T7 RNA polymerases and RNase free RQ1 DNase were from Promega Corp. The Random Primers DNA Labeling System was from Bethesda Research Laboratories.
- 15 [ $\alpha$ -<sup>32</sup>P]UTP and [ $\alpha$ -<sup>32</sup>P]dATP were from Amersham Corp. GeneScreen Plus hybridization transfer membranes were from NEN Products of Dupont and used as recommended. Oligonucleotides were synthesized using a Milligen/Bioscience cyclone DNA synthesizer and
- 20 phosphoramidite chemistry.

Example 2: Plasmid Constructions

- Standard DNA cloning techniques (Maniatis et al., Cold Spring Harbor Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1982) were
- 25 used in the construction of all plasmids. Polyoma virus strain 59RA (Feunteun et al., Proc. Natl. Acad. Sci. USA 68:283-288 (1986)) was cloned into the EcoRI site of a modified pUC18 vector and was used as the wild type virus. Constructs 5'ssa and ALM were described
- 30 previously (Adami and Carmichael, Ibid., Barrett et al., Ibid.). Plasmid BS-RZ was generated by inserting

-13-

- annealed oligonucleotides comprising the histone stem loop-ribozyme oligonucleotide shown in Figure 2B into pBlueScript SKII opened with EcoRV and SmaI. To create E-RZ, nt 359-2908 of 59RA (using the numbering system of Soeda *et al.*, Nature 283:445-453 (1980)) were inserted at the BamHI site of BS-RZ that had been filled in with Klenow enzyme. The CMV promoter excised from pcDNA I/Amp (Invitrogen Corp.) with EcoRV (nt 3023) and DraI (nt 2276) was inserted at the filled-in BamHI site of polyoma strain 59RA to create Py-CMV. Construct  $\alpha$ E-RZ was created by inserting the Klenow-filled NarI-HindIII fragment of Py-CMV containing the polyoma replication origin and the CMV promoter into the SmaI site of E-RZ. Construct Ribo-Ava was created by inserting the AvaI fragment spanning the cleavage site of the ribozyme of  $\alpha$ E-RZ. The clones used to generate RNA probes Ea and L4 were described previously (Liu and Carmichael, *Ibid.*).

Example 3: Cell Culture, Transfection, Infection and RNA Isolation

- Mouse NIH 3T3 and 3T6 cells were maintained and propagated as described by Cahill *et al.* ( J. Virol. 64:992-1001 (1990)). Cells were seeded at a density of  $1 \times 10^6$ /150-mm plate 24 hours prior to transfections or infection. For transfection, the polyoma virus constructs (wild type, ALM and 5'ssa) were released from the recombinant plasmids with proper restriction enzymes (EcoRI or BamHI) and recircularized with T4 DNA ligase under diluted conditions ( $< 10 \mu\text{g}$  DNA/ml). Transfection followed a standard BES procedure (Chen and Okayama, Mol. Cell. Biol. 7:2745-2752 (1987)). Construct  $\alpha$ E-RZ was co-transfected into NIH 3T3 cells along with mutant 5'ssa at various molar ratios as indicated in Figures 3 and 4. Infection of NIH 3T6 cells with strain 59RA was

-14-

as described by Adami and Carmichael (Nucleic Acids Res. 15:2593-2610 (1987)). A single step method using guanidinium thiocyanate (Xie and Rothblum, BioTechniques 11:325-327 (1991)) was used to isolate total RNA. In  
5 brief, cells were lysed with a solution containing 4M guanidinium thiocyanate, 25 mM sodium citrate pH 7.0, 0.5% Sarcosyl and 0.1 M mercaptoethanol. The lysate was combined with an equal volume of water-saturated phenol and one fifth volume of chloroform and then allowed to  
10 sit on ice for 15 minutes. After centrifugation the aqueous phase was removed and precipitated with an equal volume of isopropanol. Nuclear and cytoplasmic RNAs were isolated as described by Hyde-DeRuyscher and Carmichael (J. Virol. 64:5823-5832 (1990)). Nuclear and  
15 cytoplasmic RNA samples isolated 48 hours post transfection were analyzed by an RNase protection assay with the RNA probe Ribo-Ava (see Figure 2A). To minimize DNA contamination, the RNA samples were extracted twice with acidic phenol as described in Liu  
20 and Carmichael, Ibid.

#### Example 4: RNase Protection Assays

The clones used to generate RNA probes were linearized with appropriate restriction enzymes. Following in vitro transcription using T3 or T7 RNA  
25 polymerase and [ $\alpha$ -<sup>32</sup>P]UTP, DNA templates were removed by RQ1 DNase digestion in combination with acid-phenol extraction. The lengths of protected probes were 421 nt for unprocessed antisense transcripts containing *cis*-ribozyme, 337 nt for transcripts cleaved by the *cis*-  
30 ribozyme, and 305 nt for early antisense transcripts deriving from mutant 5' ssA. The labeled RNA probes were hybridized in excess to RNA samples at 57-60°C overnight (Adami et al., J. Virol. 63:85-93 (1989)). The



-15-

resulting hybrids were then digested with T1/T2 mixture (Lichtler et al., Ibid.) at 37°C for 2 hours. The reactions were stopped by adding 0.8 volumes of GTCN solution described above containing 20 µg glycogen as carrier. Undigested RNA fragments were then precipitated with an equal volume of isopropanol at -70°C. Samples recovered by centrifugation were resolved on 6% denaturing polyacrylamide sequencing gels. Quantitation of band intensities was performed using a Betascope Blot Analyzer. Control experiments using variable amounts of RNA probes confirmed that all RNase protection experiments were carried out in probe excess.

Example 5: DNA Replication Assays

Episomal DNA was isolated as described by Hirt (J. Mol. Biol. 26:365-369 (1967)) and digested with an excess of DpnI, EcoRI and BamHI. Southern blot analysis of DNA replication was as described (Cahill et al., Ibid.) with a probe made by random priming the Aval fragments (nt 657-1016) of 59RA.

Equivalents

Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims:

-16-

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

## (i) APPLICANT:

- (A) NAME: University of Connecticut
- (B) STREET: 438 Whitney Road Extension
- (C) CITY: Storrs
- (D) STATE/PROVINCE: CT
- (E) COUNTRY: USA
- (F) POSTAL CODE/ZIP: 06269-1133
- (G) TELEPHONE: (203)486-5962
- (I) TELEFAX: (203)486-5381

## (ii) TITLE OF INVENTION: Targeted RNA Degradation Using Nuclear Antisense RNA

## (iii) NUMBER OF SEQUENCES: 1

## (iv) CORRESPONDENCE ADDRESS:

- (A) ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
- (B) STREET: Two Militia Drive
- (C) CITY: Lexington
- (D) STATE: Massachusetts
- (E) COUNTRY: US
- (F) ZIP: 02173-4799

## (v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.25

## (vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER: US
- (B) FILING DATE:
- (C) CLASSIFICATION:

## (vii) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: US 08/160,058
- (B) FILING DATE: 01-DEC-1993

-17-

## (viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: Carroll Esq., Alice O.
- (B) REGISTRATION NUMBER: 33,542
- (C) REFERENCE/DOCKET NUMBER: UCT93-03

## (ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: (617) 861-6240
- (B) TELEFAX: (617) 861-9540

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 103 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: mRNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
GGAUCCCCCG AAUUAUUCG GCCCUUAUCA GGGCCAUGCA UGUCGCGGCC GCCUCCGCGG      60
CCGCCUGAUG AGUCCGUGAG GACGAACAUC GCAUAUCAAG CUU                          103
```

-18-

CLAIMS

1. A DNA construct comprising:
  - a. a transcriptional promoter;
  - b. a DNA segment; and
  - 5 c. sequences encoding a *cis*- or *trans*-  
ribozyme;such that expression of the DNA segment produces a ribonucleotide sequence which is complementary to a ribonucleotide sequence transcribed from a gene, and  
10 said expressed ribonucleotide sequence is accumulated in the cell nucleus and regulates the expression of said gene.
2. The construct of Claim 1 wherein the transcriptional promoter segment is an inducible promoter.
- 15 3. A cell containing the construct of Claim 1.
4. A vector having incorporated therein the construct of Claim 1.
5. A vector according to Claim 4 wherein said vector is a plasmid.
- 20 6. A composition comprising the construct of Claim 1 and a physiologically acceptable vehicle.
7. A composition comprising the vector of Claim 4 and a physiologically acceptable vehicle.
8. A composition comprising the vector of Claim 5 and a  
25 physiologically acceptable vehicle.
9. A cell containing the vector of Claim 4.

-19-

10. A method of regulating the expression of a gene in a cell comprising introducing the construct of Claim 1 into said cell.
11. A method of regulating the expression of a gene in a cell comprising the steps of:
  - a. introducing the construct of Claim 1 into said cell whereby a transformed cell is obtained; and
  - b. expressing the RNA segment to thereby regulate the expression of said gene.
12. A DNA construct comprising:
  - a. human cytomegalovirus promoter or Rous sarcoma virus promoter;
  - b. a DNA segment; and
  - c. sequences encoding a *cis*- or *trans*- ribozyme;such that expression of the DNA segment produces a ribonucleotide sequence which is complementary to a ribonucleotide sequence transcribed from a gene, and said expressed ribonucleotide sequence is accumulated in the cell nucleus and regulates the expression of said gene.
13. A cell containing the construct of Claim 12.
14. A vector having incorporated therein the construct of Claim 12.
15. A vector according to Claim 14 wherein said vector is a plasmid.
16. A composition comprising the construct of Claim 12 and a physiologically acceptable vehicle.

-20-

17. A composition comprising the vector of Claim 14 and a physiologically acceptable vehicle.
18. A composition comprising the vector of Claim 15 and a physiologically acceptable vehicle.
- 5 19. A method of regulating the expression of a gene in a cell comprising introducing the construct of Claim 12 into said cell.
20. A method of regulating the expression of a gene in a cell comprising the steps of:
  - 10 a. introducing the construct of Claim 12 into said cell whereby a transformed cell is obtained; and
  - b. expressing said RNA segment to thereby regulate expression of said gene.

1 / 4




FIGURE 1




FIGURE 2A




FIGURE 2B






FIG. 3

FIG. 4A





FIG. 4B



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 94/13670

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/85 C12N15/52 C12N9/00 C12N15/11 A61K31/70  
C12N5/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	PROTEIN ENGINEERING, vol. 3, no. 8, August 1990 ENGLAND GB, pages 733-737, TAIRA, K. ET AL. 'Construction of a novel artificial-ribozyme-releasing plasmid' see the whole document ---	1-5, 9-15, 19, 20
Y	MOLECULAR AND CELLULAR BIOLOGY, vol. 4, no. 4, April 1984 WASHINGTON US, pages 722-729, ACHESON, N. 'Kinetics and efficiency of polyadenylation of late polyomavirus nuclear RNA: generation of oligomeric polyadenylated RNAs and their processing into mRNA' cited in the application see the whole document --- -/-	1, 3-5, 9-11

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not  
considered to be of particular relevance"E" earlier document but published on or after the international  
filing date"L" document which may throw doubts on priority claim(s) or  
which is cited to establish the publication date of another  
citation or other special reason (as specified)"O" document referring to an oral disclosure, use, exhibition or  
other means"P" document published prior to the international filing date but  
later than the priority date claimed"T" later document published after the international filing date  
or priority date and not in conflict with the application but  
cited to understand the principle or theory underlying the  
invention"X" document of particular relevance; the claimed invention  
cannot be considered novel or cannot be considered to  
involve an inventive step when the document is taken alone"Y" document of particular relevance; the claimed invention  
cannot be considered to involve an inventive step when the  
document is combined with one or more other such docu-  
ments, such combination being obvious to a person skilled  
in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

28 March 1995

Date of mailing of the international search report

04. 04. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Andres, S

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 94/13670

## C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JOURNAL OF VIROLOGY, vol. 65, no. 10, October 1991 pages 5531-5534, WEERASINGHE, M. ET AL. 'Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD41 lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme' see page 5532, left column, line 1 - line 23 ---	2, 12-15, 19, 20
A	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 86, no. 13, July 1989 WASHINGTON US, pages 4823-4827, DZIANOTT, A. & BUJARSKI, J. 'Derivation of an infectious viral RNA by autolytic cleavage of in vitro transcribed viral cDNAs' see abstract see figure 1 see page 4826, line 1 - line 6 ---	1
A	EMBO JOURNAL, vol. 8, no. 12, 1989 EYNSHAM, OXFORD GB, pages 3861-3866, COTTEN, M. & BIRNSTIEL, M. 'Ribozyme mediated destruction of RNA in vivo' see abstract see page 3861, right column, paragraph 3 see page 3863, left column, paragraph 2 see page 3865, left column, paragraph 3 - right column, last paragraph ---	1
A	ERICKSON, R. & IZANT, J. 'Gene regulation: biology of antisense RNA and DNA' 1992, RAVEN PRESS, LTD., NEW YORK pages 35-54; TAIRA, K. & NISHIKAWA, S.: 'Construction of several kinds of ribozymes' see page 36 - page 42 ---	1
P, X	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 91 (10). 4258-4262, 10 May 1994 LIU, Z. ET AL. 'Targeted nuclear antisense RNA mimics natural antisense -induced degradation of polyoma virus early RNA.' see the whole document ---	1-20

-/--

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 94/13670

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	MOLECULAR BIOTECHNOLOGY 2 (2). 1994. 107-118., LIU, Z. & CARMICHAEL, G. 'Nuclear antisense RNA: An efficient new method to inhibit gene expression.' see the whole document -----	1

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 94/ 13670**Box I** Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 10-11, 19-20 (as far as in vivo methods are concerned) are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II** Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.